TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20008210
Drug: Statin medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin medications
Study: 15266759
Drug: Vaginal sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal sildenafil (25 mg four times daily intravaginally)
Study: 7728133
Drug: FTBI/VP-16 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTBI/VP-16 regimen with added CY 60 mg/kg
Study: 26650152
Drug: Permethrin group
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permethrin group (mass administration of permethrin)
Study: 26650152
Drug: Ivermectin group
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin group (mass administration of ivermectin)
Study: 15003080
Drug: Paroxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine + Clonazepam (1.0 to 2.0 mg/day, divided b.i.d.)
Study: 11762415
Drug: Zevalin (ibritumomab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zevalin (ibritumomab tiuxetan) at a dose of 0.4 mCi/kg for patients with platelet counts > 150,000 and < 25% bone marrow involvement; 0.3 mCi/kg for patients with platelet counts between 100,000-149,000.
Study: 11762415
Drug: Rituximab at
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab at a standard dose of 375 mg/m2 weekly for four weeks (control group).
Study: 11762415
Drug: Phase II
Normalized name: Coxiella burnetii phase II Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II study of reduced dose of Zevalin in patients with mild thrombocytopenia.
Study: 9327113
Drug: Marezine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marezine (50 mg)
Study: 9327113
Drug: Dramamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dramamine (50 mg)
Study: 2564563
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg daily
Study: 25409592
Drug: Hydrocortisone (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (160 mg/day)
Study: 12590012
Drug: Low-dose hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormonal replacement therapy (LD‐HRT), 17beta‐estradiol (1 mg/day) and norethisterone acetate (0.5 mg/day)
Study: 12590012
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (controls)
Study: 31411779
Drug: Randomised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised treatment
Study: 6756936
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg plus codeine 20 mg
Study: 6756936
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg plus codeine 40 mg
Study: 28736511
Drug: MSM (OptiMSM®)
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSM (OptiMSM®) at 3 g/day for 21 days prior to the race and for two days after (23 total)
Study: 21942465
Drug: Etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 400 mg twice a day
Study: 21942465
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg thrice a day
Study: 12829141
Drug: Postoperative RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative RT combined with mitomycin C (15 mg/m2 after 10 Gy) and bleomycin (5 mg twice a week during RT to a total of 70 mg)
Study: 10817348
Drug: Epirubicin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (120 mg/m2, i.v. bolus every 3 weeks)
Study: 8664976
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) alone (2 IU m‐2 sc q.i.d.)
Study: 2052337
Drug: Cephalexin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin, 250 mg four times a day
Study: 6619055
Drug: Piperacillin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (300 mg/kg/day) alone
Study: 6619055
Drug: Piperacillin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (300 mg/kg/day) and tobramycin (7 mg/kg/day) iv
Study: 30577903
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (Treatment as usual)
Study: 20175431
Drug: EGCG 270
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG 270 mg
Study: 20175431
Drug: Placebo 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 270 mg
Study: 20175431
Drug: EGCG 270
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG 270 mg + Caffeine 3 mg/kg
Study: 17471993
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OT)
Study: 7611390
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (1.62 +/- 0.02 g protein.kg-1.day-1)
Study: 7611390
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein diet (0.80 +/- 0.02 g protein.kg-1.day-1)
Study: 2223335
Drug: Flumazenil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.01 mg kg‐1 administered 5 min after midazolam
Study: 2223335
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg and 5 mg i.v.
Study: 28988
Drug: Theophylline-Ephedrine combination
Normalized name: Theophylline, Ephedrine Hydrochloride, and Phenobarbital Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline-Ephedrine combination
Study: 28988
Drug: Ephedrine-Butabarbital combination
Normalized name: butabarbital / ephedrine / guaifenesin / theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine-Butabarbital combination
Study: 28545998
Drug: Aflibercept 4
Normalized name: aflibercept 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 4 mg/kg
Study: 28545998
Drug: Aflibercept 1
Normalized name: aflibercept 114 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 1 mg/kg
Study: 21465518
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with assessment of bone marrow cytology on day 6
Study: 16709019
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via convection-enhanced delivery (CED)
Study: 16709019
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via bolus injection
Study: 8228934
Drug: Four-dose vaccination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose vaccination scheme starting at month 3 (months 3, 4, 5, and 11)
Study: 8228934
Drug: Three-dose vaccination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose vaccination scheme starting at birth (months 0, 1, and 6)
Study: 8228934
Drug: Four-dose vaccination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose vaccination scheme starting at birth (months 0, 1, 2, and 11)
Study: 2878016
Drug: Combined H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined H1 (diphenhydramine hydrochloride) and H2 (cimetidine) histamine antagonists
Study: 2878016
Drug: H1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1 antagonist (diphenhydramine hydrochloride) alone
Study: 28655271
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises
Study: 28655271
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises (subgroup analysis)
Study: 25487932
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injection (15 IU to 45 IU, average 31.2±13.9 IU) plus conventional physical therapy
Study: 25487932
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (PY)
Study: 20618883
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g cholestyramine powder
Study: 20618883
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g cholestyramine powder
Study: 12051571
Drug: Dexloxiglumide 100
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexloxiglumide 100 mg
Study: 12051571
Drug: Dexloxiglumide 200
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexloxiglumide 200 mg
Study: 12051571
Drug: Dexloxiglumide 400
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexloxiglumide 400 mg
Study: 12051571
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of Dexloxiglumide 100 mg
Study: 12051571
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of Dexloxiglumide 200 mg
Study: 12051571
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of Dexloxiglumide 400 mg
Study: 12051571
Drug: Dexloxiglumide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexloxiglumide (all doses)
Study: 7192147
Drug: Psychoergic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoergic drugs (3 stimulants)
Study: 6405838
Drug: Postoperative total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative total parenteral nutrition (TPN)
Study: 6405838
Drug: TPN-5-FU combination
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TPN-5-FU combination
Study: 22566588
Drug: Ritonavir 50
Normalized name: ritonavir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 50 mg
Study: 17645681
Drug: FACT-G based
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT-G based algorithm
Study: 10447324
Drug: Sacolene (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacolene (4 g at start and 2 g 4 hourly until cessation of diarrhoea)
Study: 372858
Drug: gamma-ethylester of
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-ethylester of glutamic acid (25 g)
Study: 372858
Drug: l-arginine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (25 g)
Study: 372858
Drug: placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (physiological solution in identical 500 ml bottles)
Study: 30371811
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfuse hemoglobin <7 g/dL) in massive burns
Study: 30371811
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfuse hemoglobin <10 g/dL) in massive burns
Study: 29734777
Drug: Sunrouge extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunrouge extract containing 11.2 mg anthocyanin and 323.6 mg EGCG
Study: 29734777
Drug: Yabukita extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yabukita extract containing 322.2 mg EGCG
Study: 21805328
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg daily for up to 6 months)
Study: 17456652
Drug: Dexamethasone 0.0625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.0625 mg/kg
Study: 17456652
Drug: Dexamethasone 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.125 mg/kg
Study: 17456652
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg/kg
Study: 19066382
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg
Study: 17456652
Drug: Dexamethasone 1.0
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL / DEXAMETHASONE 1.0 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.0 mg/kg
Study: 9241003
Drug: Brofaromine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (50 mg/day titrated to 150 mg/day)
Study: 8390340
Drug: Gonadotropin releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone agonist (GnRHA) with low doses of oral estrogen (0.625 mg conjugated estrogen, CE for 6 days/week) and intermittent oral progestogen (10 mg medroxyprogesterone acetate, MPA for 13 days every 4 months)
Study: 2892259
Drug: Nizatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (150 mg h.s.)
Study: 26938761
Drug: Regular treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatments (Control)
Study: 24161413
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (Shanchol™), two doses
Study: 24161413
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus safe water and hand washing practice
Study: 19451353
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (402 mg every other day)
Study: 16756056
Drug: Dalacin C
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dalacin C (original preparation)
Study: 15531858
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day oral isoflavones
Study: 15531858
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day oral isoflavones
Study: 15531858
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day transdermal isoflavones
Study: 15531858
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day transdermal isoflavones
Study: 11745230
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI)
Study: 11745230
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (PEI) alone
Study: 11745230
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with TACE-PEI
Study: 11745230
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with TACE-PEI (for tumors < 2 cm)
Study: 6363216
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy at intervals of one week
Study: 6363216
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy at intervals of three weeks
Study: 31842811
Drug: Vaginal dose
Normalized name: Product manufactured as vaginal dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dose of radical radiotherapy (using PIBS point system)
Study: 25243962
Drug: Fufang Biejia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Biejia Ruangan Tablet plus entecavir (Group A, n=56)
Study: 25243962
Drug: Fufang Biejia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Biejia Ruangan tablet only (Group C, n=55)
Study: 22007735
Drug: Proprioceptive neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive neuromuscular facilitation (PNF) techniques (rhythmic initiation, dynamic reversion, isotonic combination)
Study: 10080511
Drug: Once-daily vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily vigabatrin administration
Study: 10080511
Drug: Twice-daily vigabatrin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily vigabatrin administration
Study: 1559299
Drug: Biosynthetic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic growth hormone (GH) for 6 months
Study: 23361591
Drug: Histidine supplementation
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histidine supplementation (4 g/day for 12 weeks)
Study: 23361591
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g/day for 12 weeks)
Study: 19845233
Drug: Alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha tocopherol (525 IU) administered orally at 48 hr, 24 hr, and in the morning prior to coronary procedures
Study: 19845233
Drug: Placebo compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo compound administered orally at 48 hr, 24 hr, and in the morning prior to coronary procedures
Study: 8200011
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/day + omega-3 polyunsaturated fatty acids (n3-PUFA)
Study: 3709642
Drug: sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual isosorbide dinitrate (ISDN) 5 mg
Study: 22018131
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills
Study: 24785951
Drug: Hormonal implants
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal implants
Study: 22730912
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with methylene blue 450 μg/mL and low-power laser
Study: 22730912
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with wavelength 660 nm, power of 30 mW, fluence of 7.5 J/cm(2)
Study: 22730912
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg/day for 14 days
Study: 20970760
Drug: Structured aerobic
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured aerobic exercise regimen (weekly supervised exercise sessions over a 10-week period, including education, warm-up, 30 minutes of aerobic exercise, and cool down, with exercise intensity adjusted to reach a heart rate goal of 60% of the participant's estimated maximal heart rate)
Study: 16001382
Drug: Anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave acetate 15 mg for depot suspension
Study: 10601917
Drug: Intravaginally administered
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginally administered moistened misoprostol tablets (800 microg, repeated 24 hours later if needed)
Study: 10601917
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg) followed by oral misoprostol (400 microg)
Study: 10601917
Drug: Intravaginally administered
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginally administered moistened misoprostol tablets
Study: 10601917
Drug: Mifepristone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone and oral misoprostol
Study: 7793544
Drug: droperidol 1
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 1 mg
Study: 6157007
Drug: Azathioprine therapy
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine therapy (2 mg/kg body weight daily)
Study: 28521540
Drug: LMWH/VKA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH/VKA therapy
Study: 21301819
Drug: MK-0249 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249 (10 mg)
Study: 21301819
Drug: MK-0249 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0249 (50 mg)
Study: 17722823
Drug: Methycobal 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methycobal 250 microg intramuscular injection plus acupuncture at Guanyuan (CV 4), Shenshu (BL 23), Ciliao (BL 32), Huiyang (BL 35), once every day
Study: 17722823
Drug: Methycobal 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methycobal 250 microg intramuscular injection, once every other day
Study: 15096240
Drug: Paravertebral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral injection of radio‐opaque dye (10 ml) with co‐administration of 20 ml of local anaesthetics, ventral to the endothoracic fascia
Study: 15096240
Drug: Paravertebral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral injection of radio‐opaque dye (10 ml) without co‐administration of local anaesthetics, dorsal to the endothoracic fascia
Study: 30060030
Drug: Oncological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncological therapies
Study: 25619410
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (AZL‐M) 40 mg once a day (QD), titrated to 80 mg at week 4, with optional addition of chlorthalidone (CLD) 25 mg QD (weeks 8-22) if required.
Study: 23789212
Drug: Perilla oil
Normalized name: Perilla frutescens leaf oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla oil treatment for 8 weeks